the art approaches and using many more protein ligand complexes than previously reported. The models displayed similar performance on the PDBbind core set suggesting they were behaving as expected, and the additional data led to further improvement. Therefore, we set a difficult but realistic challenge to understand if such models can be used for new drug discovery targets. We deliberately chose a large number of test cases to avoid bias and aid analysis. Twelve drug discovery LO datasets were not used for training and instead reserved for external testing. Each dataset corresponds to a unique protein target that overall cover several typical drug discovery relevant protein families. Models trained with and without the drug discovery LO data training sets were tested against these target sets.